Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kathryn Humphrey
Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Related publications
Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
OncoTargets and Therapy
Oncology
Pharmacology
PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
